Recordati : Operating performance holding up well despite the top-line below expectations
>Rare diseases are a growth driver - Recordati reported on Friday during trading its figures for Q3 2024. Sales over the period are 2.8% below forecasts at € 557.4m (+9% y-o-y). We highlight: i/ growth momentum still driven by the rare diseases segment (+14.5% cc) for 9M, with business continuing to benefit from endocrinology (+36%) and oncology (+17%); ii/ growth in the SPC franchise is still robust at 9% (+6.5% cc), but more impacted than expected by the Cough&Cold ...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.